Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04067622 · ClinicalTrials.gov registry record · NA

Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment

A NA study of Critical Illness and Sepsis, sponsored by University of Vermont.

Completed
Registry status
NA
Development phase
58
Enrollment target
3
Study locations

NCT04067622 is a NA study of Critical Illness and Sepsis that has completed, run by University of Vermont. The registered enrollment target is 58 participants, below the 3,138-participant average among 91 other Critical Illness trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04067622, a NA study of Critical Illness and Sepsis, has completed, sponsored by University of Vermont.

COMPLETED
Registry status
NA
Development phase
58 participants
Enrollment target
3
Study locations

Study Summary

This study evaluates a novel arm restraint compared with traditional soft wrist restraints in older critically ill patients. The primary outcome is upper extremity mobility measured by actigraphy, and secondary outcomes include sedation, agitation, satisfaction, and acceptability.

Interventions

  • DEVICE Exersides

Study Locations (3)

California

  • University of California San Diego - San Diego

Maryland

  • Johns Hopkins University - Baltimore

Vermont

  • University of Vermont - Burlington

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2019-09-01
Est. Completion 2021-12-28
Phase NA

Sponsor

University of Vermont

162 total trials

What the Registry Record Tells You About NCT04067622

The ClinicalTrials.gov registry entry for NCT04067622 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,138-participant average among 91 other Critical Illness trials with a reported enrollment target (98% lower). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Critical Illness appearing as the primary indexed condition, and to 1 intervention - of which Exersides is the first listed.

NCT04067622 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Maryland, Vermont.

Frequently Asked Questions

What is clinical trial NCT04067622 about?

NCT04067622 is a clinical study titled "Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment". This study evaluates a novel arm restraint compared with traditional soft wrist restraints in older critically ill patients. The primary outcome is upper extremity mobility measured by actigraphy, and secondary outcomes include sedation, agitation, satisfaction, and acceptability.

What is the current status of trial NCT04067622?

This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2019-09-01. Estimated completion is 2021-12-28.

What conditions does trial NCT04067622 study?

This clinical trial studies the following conditions: Critical Illness, Sepsis, ARDS, Acute Respiratory Failure, Encephalopathy.

What interventions are being tested in trial NCT04067622?

The interventions under investigation include: Exersides (DEVICE).

Who is sponsoring clinical trial NCT04067622?

This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04067622 being conducted?

This trial has 3 study locations across California, Maryland, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Critical Illness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.